Close
Nordic 9Nordic 9

Neovacs (investor - Corporate Investor)

France neovacs.fr
See something wrong or missing? Let us know
Offices:Paris

Neovacs is a French biotech company that develops several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune and allergic diseases.

Average round investment:1.51M USD
Average number per year:1.0
Distribution: 2021 (1)
Portfolio companies: France Signia Therapeutics
Mostly invests in: France France (1) Health services (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Neovacs

Name Criteria
Belgium Newton Biocapital
73%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Sophia Antipolis Business Angels
73%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Val de France Business Angels
73%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Hampus Jakobsson
71%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 4.8
  • Active last 12 months: Yes
France Extens
70%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Germany Peppermint Venture Partners
70%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Hong Kong MCG Technology Group
70%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Catapult Ventures
70%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Italy Gruppo Brixia
70%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Stockholm University Holding AB
70%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top